New ADHD medication on the horizon
Fuente:
Wiley Open Access
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867021737172926464 |
|---|---|
| author | Alison Knopf |
| author_facet | Alison Knopf Alison Knopf |
| collection | Wiley Open Access |
| contents | New ADHD medication on the horizon Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Otsuka has announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once‐daily extended‐release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention‐deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations. 10.1002/cpu.31041 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/cpu.31041 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cpu_31041 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | New ADHD medication on the horizon Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update New ADHD medication on the horizon Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Otsuka has announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once‐daily extended‐release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention‐deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations. 10.1002/cpu.31041 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | New ADHD medication on the horizon |
| topic | The Brown University Child & Adolescent Psychopharmacology Update |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cpu.31041 |